Preventive Tuberculosis Services Reduces the Risk of Local Forms of Tuberculosis Development in Children on Immunosuppressive Therapy: Retrospective Cohort Study

Preventive Tuberculosis Services Reduces the Risk of Local Forms of Tuberculosis Development in Children on Immunosuppressive Therapy: Retrospective Cohort Study

Background. Long-term immunosuppressive therapy in children (including genetically engineered biologic drugs, GEBD) is associated with a high risk of local tuberculosis (TB) development. Objective. The aim of the study was to examine efficacy of tuberculosis services in children with high risk of de...

Full description

Bibliographic Details
Main Authors:	Valentina A. Aksenova, Nadezda I. Klevno, Alexey V. Kazakov, Dmitry A. Kudlay, Tatyana A. Sevostyanova, Elena К. Dementyeva
Format:	Article
Language:	English
Published:	"Paediatrician" Publishers LLC 2020-12-01
Series:	Вопросы современной педиатрии
Subjects:	туберкулез проба манту аллерген туберкулезный рекомбинантный (диаскинтест) аутоиммунные системные заболевания ревматоидный артрит генно-инженерные биологические препараты
Online Access:	https://vsp.spr-journal.ru/jour/article/view/2494

Similar Items

EFFICIENCY OF USING TUBERCULOUS RECOMBINANT ALLERGEN FOR SCREENING FOR TUBERCULOUS INFECTION IN CHILDREN AND ADOLESCENTS IN STAVROPOL KRAY
by: O. D. Baronova, et al.
Published: (2016-08-01)

Возможные причины и механизмы возникновения нежелательных побочных реакций немедленного типа на генноинженерные туберкулезные аллергены у детей
by: Александр Михайлович Королюк, et al.
Published: (2019-03-01)

Recombinant in vitro test T-SPOT.TB as a screening method for early diagnosis of tuberculosis infection
by: E. P. Eremenko, et al.
Published: (2020-05-01)

DETECTION AND DIFFERENTIAL DIAGNOSTICS OF TUBERCULOSIS IN CHILDREN AND ADOLESCENTS
by: L. A. BАRYSHNIKOVА, et al.
Published: (2017-10-01)

Comparative evaluation of immunological tests for at-risk children in Tomsk Region
by: N. N. Kabanets, et al.
Published: (2017-01-01)

CRITERIA OF TUBERCULOSIS TREATMENT EFFICIENCY IN CHILDREN UNDER CURRENT CONDITIONS
by: N. A. Barmina, et al.
Published: (2017-11-01)

Safety of using genetic engineering biological agents in rheumatoid arthritis
by: N V Chichasova, et al.
Published: (2010-03-01)

Comparative Evaluation of Allergodiagnostic of Tuberculosis in Children
by: I. V. Mikheeva, et al.
Published: (2016-06-01)

RHEUMATIC DISEASES AND TUBERCULOSIS INFECTION IN CHILDREN AND ADULTS
by: G. V. Santalova, et al.
Published: (2019-03-01)

USE OF THE NEW GENETIC ENGINEERING BIOLOGICAL AGENT TOCILIZUMABIN THE TREATMENT OF RHEUMATOID ARTHRITIS
by: E L Nasonov, et al.
Published: (2010-03-01)

Biological agents for endoprosthetic joint replacement in patients with rheumatoid arthritis
by: Viktoria Nikolaevna Khlaboshina, et al.
Published: (2014-12-01)

A CURRENT VIEW ON THE PROBLEM OF RAPIDLY PROGRESSIVE RHEUMATOID ARTHRITIS
by: Dmitry Evgenyevich Karateyev
Published: (2010-06-01)

Immunodiagnostics of tuberculosis infection <i>in vitro</i> in solving the issue of prescribing preventive chemotherapy
by: E. P. Eremenko, et al.
Published: (2020-09-01)

Long-term results of using the skin test with tuberculosis recombinant allergen for tuberculosis detection in Stavropol Region
by: O. D. Baronova, et al.
Published: (2019-05-01)

Rheumatoid arthritis in real clinical practice: initiation of therapy with biological agents. Results of the «Computer Terminals of Self-Assessment for Patients with Rheumatic Diseases» («TERMINAL-II») project
by: V. N. Amirdzhanova, et al.
Published: (2019-09-01)

TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS WITH COMBINED PATHOLOGY
by: D. I. Khusainova, et al.
Published: (2020-06-01)

Combination therapy with leflunomide and genetic engineering biological agents
by: Nataliya Vladimirovna Chichasova, et al.
Published: (2011-06-01)

EFFICASY OF A NEW PREPARATION FOR TUBERCULOSIS DIAGNOSTICS IN CHILDREN AND ADOLESCENTS
by: L. A. Barishnikova, et al.
Published: (2012-09-01)

Efficacy of the Recombinant Tuberculosis Allergen for Early Identification of Latent Tuberculosis in Children and Adolescents in General Healthcare Settings
by: V. A. Aksenova, et al.
Published: (2015-08-01)

Experience with long-term use of certolizumab pegol (Cimzia)
by: Karine Arnoldovna Lytkina, et al.
Published: (2013-10-01)

The tumor necrosis factor-α inhibitor golimumab in the treatment of rheumatoid arthritis
by: Natalia Vladimirovna Chichasova
Published: (2014-12-01)

Pharmacoeconomic analysis of using biological agents in the treatment of rheumatoid arthritis
by: I. I. Dyakov, et al.
Published: (2014-09-01)

The prediction and long-term maintenance of low disease activity during therapy with disease modifying anti-inflammatory drugs for rheumatoid arthritis
by: E.L. Luchikhina
Published: (2014-05-01)

TB SKIN TEST RESPONSE IN CHILDREN WITH HIV INFECTION
by: N. I. Klevno
Published: (2014-07-01)

The problem of laboratory monitoring in therapy with disease-modifying antirheumatic drugs and biological agents in patients with rheumatoid arthritis
by: Yu. V. Muravyev, et al.
Published: (2018-09-01)

EXPERIENCE OF USING TUBERCULOUS RECOMBINANT ALLERGEN FOR DIAGNOSTICS OF TUBERCULOSIS IN HIV PATIENTS
by: N. V. Eysmont
Published: (2015-10-01)

Tuberculous recombinant allergen as a part of preventive examination for tuberculosis among patients of 24-hour social service institutions
by: A. A. Shurygin, et al.
Published: (2019-08-01)

Rheumatoid arthritis: problems of treatment at the present stage
by: N. V. Chichasova
Published: (2018-12-01)

Possible reasons for the inefficacy of genetically engineered biological agents in rheumatoid arthritis and ways of its prevention
by: Natalia Vladimirovna Chichasova
Published: (2012-06-01)

Experience with tofacitinib in the treatment of resistant rheumatoid arthritis
by: A. R. Babaeva, et al.
Published: (2015-06-01)

POSSIBILITIES FOR PRESERVING THE RESULTS OF TREATMENT IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AFTER DOSE REDUCTION AND/OR DISCONTINUATION OF BIOLOGICAL AGENTS: A REMARCA STUDY
by: E. L. Luchikhina, et al.
Published: (2016-12-01)

Difficult-to-treat rheumatoid arthritis in the clinical practice of a rheumatological hospital. First look
by: A. V. Gordeev, et al.
Published: (2022-05-01)

Abatacept and cardiovascular risk in rheumatoid arthritis: update
by: T. V. Popkova
Published: (2018-01-01)

The marked and rapid therapeutic effect of tofacitinib in combination with subcutaneous methotrexate in a rheumatoid arthritis patient with poor prognostic factors who is resistant to standard disease-modifying antirheumatic drugs and biologicals: A clinical case
by: N. V. Demidova, et al.
Published: (2016-03-01)

USE OF RITUXIMAB IN AUTOIMMUNE DISEASES: NEW ASPECTS
by: Dmitry Evgenyevich Karateyev
Published: (2010-09-01)

Diagnostic value of immunological skin tests in children with tuberculosis
by: A. G. Smetanin, et al.
Published: (2015-01-01)

Current approaches to screening for tuberculosis infection in children and adolescents in Russia
by: V. A. Aksenova, et al.
Published: (2015-12-01)

Comorbid infections in patients with rheumatoid arthritis
by: B.S. Belov
Published: (2014-05-01)

Immunopathogenetic mechanisms of action of ustekinumab, a new drug for the treatment of psoriatic arthritis and psoriasis
by: T. V. Korotaeva, et al.
Published: (2015-06-01)

Rationales for discontinuation of disease-modifying antirheumatic drugs, biologic agents, and tofacitinib in rheumatoid arthritis
by: Yu. V. Muraviev, et al.
Published: (2018-12-01)